BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 12391221)

  • 1. HLA-DR4 molecules in neuroendocrine epithelial cells associate to a heterogeneous repertoire of cytoplasmic and surface self peptides.
    Muntasell A; Carrascal M; Serradell L; Veelen Pv Pv; Verreck F; Koning F; Raposo G; Abián J; Jaraquemada D
    J Immunol; 2002 Nov; 169(9):5052-60. PubMed ID: 12391221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissection of the HLA-DR4 peptide repertoire in endocrine epithelial cells: strong influence of invariant chain and HLA-DM expression on the nature of ligands.
    Muntasell A; Carrascal M; Alvarez I; Serradell L; van Veelen P; Verreck FA; Koning F; Abian J; Jaraquemada D
    J Immunol; 2004 Jul; 173(2):1085-93. PubMed ID: 15240697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA-DM can partially replace the invariant chain for HLA-DR transport and surface expression in transfected endocrine epithelial cells.
    Serradell L; Muntasell A; Catálfamo M; Martí M; Costa M; de Préval C; Jaraquemada D
    Tissue Antigens; 1999 May; 53(5):447-58. PubMed ID: 10372540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantigenic HCgp39 epitopes are presented by the HLA-DM-dependent presentation pathway in human B cells.
    Patil NS; Hall FC; Drover S; Spurrell DR; Bos E; Cope AP; Sonderstrup G; Mellins ED
    J Immunol; 2001 Jan; 166(1):33-41. PubMed ID: 11123274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polarized transport of MHC class II molecules in Madin-Darby canine kidney cells is directed by a leucine-based signal in the cytoplasmic tail of the beta-chain.
    Simonsen A; Pedersen KW; Nordeng TW; von der Lippe A; Stang E; Long EO; Bakke O
    J Immunol; 1999 Sep; 163(5):2540-8. PubMed ID: 10452991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rheumatoid arthritis (RA)-associated HLA-DR alleles form less stable complexes with class II-associated invariant chain peptide than non-RA-associated HLA-DR alleles.
    Patil NS; Pashine A; Belmares MP; Liu W; Kaneshiro B; Rabinowitz J; McConnell H; Mellins ED
    J Immunol; 2001 Dec; 167(12):7157-68. PubMed ID: 11739539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentation.
    Carstens C; Newman DK; Bohlen H; König A; Koch N
    Int Immunol; 2000 Nov; 12(11):1561-8. PubMed ID: 11058576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional HLA-DM on the surface of B cells and immature dendritic cells.
    Arndt SO; Vogt AB; Markovic-Plese S; Martin R; Moldenhauer G; Wölpl A; Sun Y; Schadendorf D; Hämmerling GJ; Kropshofer H
    EMBO J; 2000 Mar; 19(6):1241-51. PubMed ID: 10716924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discoordinate surface expression of IFN-gamma-induced HLA class II proteins in nonprofessional antigen-presenting cells with absence of DM and class II colocalization.
    Muczynski KA; Anderson SK; Pious D
    J Immunol; 1998 Apr; 160(7):3207-16. PubMed ID: 9531276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired antigen presentation by murine I-Ad class II MHC molecules expressed in normal and HLA-DM-defective human B cell lines.
    Weenink S; Averdunk H; Boston T; Boswarva V; Guery JC; Adorini L; Mellins E; McCluskey J; Gautam AM
    Int Immunol; 1997 Jun; 9(6):889-96. PubMed ID: 9199972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cell selection and differential activation on structurally related HLA-DR4 ligands.
    Gebe JA; Novak EJ; Kwok WW; Farr AG; Nepom GT; Buckner JH
    J Immunol; 2001 Sep; 167(6):3250-6. PubMed ID: 11544312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor cells present MHC class II-restricted nuclear and mitochondrial antigens and are the predominant antigen presenting cells in vivo.
    Qi L; Rojas JM; Ostrand-Rosenberg S
    J Immunol; 2000 Nov; 165(10):5451-61. PubMed ID: 11067897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variation in HLA-DM expression influences conversion of MHC class II alpha beta:class II-associated invariant chain peptide complexes to mature peptide-bound class II alpha beta dimers in a normal B cell line.
    Ramachandra L; Kovats S; Eastman S; Rudensky AY
    J Immunol; 1996 Mar; 156(6):2196 - 2204. PubMed ID: 8690909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A defective viral superantigen-presenting phenotype in HLA-DR transfectants is corrected by CIITA.
    Azar GA; Sékaly RP; Thibodeau J
    J Immunol; 2005 Jun; 174(12):7548-57. PubMed ID: 15944254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T cell epitopes of human myelin oligodendrocyte glycoprotein identified in HLA-DR4 (DRB1*0401) transgenic mice are encephalitogenic and are presented by human B cells.
    Forsthuber TG; Shive CL; Wienhold W; de Graaf K; Spack EG; Sublett R; Melms A; Kort J; Racke MK; Weissert R
    J Immunol; 2001 Dec; 167(12):7119-25. PubMed ID: 11739534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Herpes simplex virus type 1 targets the MHC class II processing pathway for immune evasion.
    Neumann J; Eis-Hübinger AM; Koch N
    J Immunol; 2003 Sep; 171(6):3075-83. PubMed ID: 12960333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of the class II MHC pathway in primary human monocytes by granulocyte-macrophage colony-stimulating factor.
    Hornell TM; Beresford GW; Bushey A; Boss JM; Mellins ED
    J Immunol; 2003 Sep; 171(5):2374-83. PubMed ID: 12928384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Editing of the HLA-DR-peptide repertoire by HLA-DM.
    Kropshofer H; Vogt AB; Moldenhauer G; Hammer J; Blum JS; Hämmerling GJ
    EMBO J; 1996 Nov; 15(22):6144-54. PubMed ID: 8947036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Editing of an immunodominant epitope of glutamate decarboxylase by HLA-DM.
    Lich JD; Jayne JA; Zhou D; Elliott JF; Blum JS
    J Immunol; 2003 Jul; 171(2):853-9. PubMed ID: 12847254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MHC class II-associated invariant chain peptide replacement by T cell epitopes: engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation.
    Malcherek G; Wirblich C; Willcox N; Rammensee HG; Trowsdale J; Melms A
    Eur J Immunol; 1998 May; 28(5):1524-33. PubMed ID: 9603457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.